Shanafelt TD - Search Results

1

Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.

Cerhan JR, Fredericksen ZS, Wang AH, Habermann TM, Kay NE, Macon WR, Cunningham JM, Shanafelt TD, Ansell SM, Call TG, Witzig TE, Slager SL, Liebow M. Cerhan JR, et al. Among authors: shanafelt td. Int J Mol Epidemiol Genet. 2011;2(2):95-113. Epub 2011 Apr 5. Int J Mol Epidemiol Genet. 2011. PMID: 21686124 Free PMC article.

2

Medical residents' emotional well-being.

Shanafelt T, Habermann T. Shanafelt T, et al. JAMA. 2002 Oct 16;288(15):1846-7; author reply 1847. doi: 10.1001/jama.288.15.1846. JAMA. 2002. PMID: 12377076 No abstract available.

3

The well-being of physicians.

Shanafelt TD, Sloan JA, Habermann TM. Shanafelt TD, et al. Am J Med. 2003 Apr 15;114(6):513-9. doi: 10.1016/s0002-9343(03)00117-7. Am J Med. 2003. PMID: 12727590 No abstract available.

4

Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.

Shanafelt TD, Geyer SM, Kay NE. Shanafelt TD, et al. Blood. 2004 Feb 15;103(4):1202-10. doi: 10.1182/blood-2003-07-2281. Epub 2003 Oct 23. Blood. 2004. PMID: 14576043 Free article. Review.

5

Current approach to diagnosis and management of chronic lymphocytic leukemia.

Shanafelt TD, Call TG. Shanafelt TD, et al. Mayo Clin Proc. 2004 Mar;79(3):388-98. doi: 10.4065/79.3.388. Mayo Clin Proc. 2004. PMID: 15008611 Review.

6

Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies.

Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. Shanafelt TD, et al. Leuk Res. 2006 Jun;30(6):707-12. doi: 10.1016/j.leukres.2005.10.020. Epub 2005 Dec 1. Leuk Res. 2006. PMID: 16325256

7

Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.

Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM. Novak AJ, et al. J Clin Oncol. 2006 Feb 20;24(6):983-7. doi: 10.1200/JCO.2005.02.7938. Epub 2006 Jan 23. J Clin Oncol. 2006. PMID: 16432079

8

The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.

Shanafelt TD, Kay NE. Shanafelt TD, et al. Semin Oncol. 2006 Apr;33(2):174-85. doi: 10.1053/j.seminoncol.2006.01.008. Semin Oncol. 2006. PMID: 16616064 Review.

9

Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.

Stockero KJ, Fink SR, Smoley SA, Paternoster SF, Shanafelt TD, Call TG, Zent CS, Van Dyke DL, Kay NE, Dewald GW. Stockero KJ, et al. Among authors: shanafelt td. Cancer Genet Cytogenet. 2006 Apr 15;166(2):152-6. doi: 10.1016/j.cancergencyto.2005.10.011. Cancer Genet Cytogenet. 2006. PMID: 16631472

10

Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.

Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald GW. Fink SR, et al. Among authors: shanafelt td. Cancer Genet Cytogenet. 2006 Jun;167(2):177-81. doi: 10.1016/j.cancergencyto.2006.01.005. Cancer Genet Cytogenet. 2006. PMID: 16737921

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

524 results

Search Page